Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Plasma-only multiomic minimal residual disease (MRD) testing in 2,000 consecutive patients with colorectal cancer (CRC).
Authors
Katrina Sophia Pedersen
Washington University School of Medicine in St. Louis, St. Louis, MO;
Katrina Sophia Pedersen , Benjamin R. Tan , Xiaotong Zuo , Lesli A. Kiedrowski , Leslie Bucheit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 28)
DOI
10.1200/JCO.2023.41.4_suppl.28
Abstract #
28
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
First Author: Giulia Maddalena
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Predicting recurrence using a tumor-uninformed ctDNA assay detecting MRD in patients with resected stage II or III colorectal cancer: Subset analysis from the GALAXY study in CIRCULATE-Japan.
First Author: Yoshiaki Nakamura
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Multiomic analysis for minimal residual disease detection: Addressing challenges in stage II-III colon cancer from COSMOS-CRC-01.
First Author: Yoshiaki Nakamura
Poster
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
First Author: Arvind Dasari